Metabolic disorders in case of androgen deprivation: the role of endocrinologist in the management of the case


DOI: https://dx.doi.org/10.18565/therapy.2018.5.91-95

T.Ju. Demidova, E.Ju. Gritzkevitch, S.V. Mishugin

1 Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU», Moscow, Russia; 2 State Budgetary Healthcare Institution D.D. Pletnyov city clinical hospital, Moscow, Russia
Androgen depriving therapy (ADT) is widely used around the world for the treatment of various stages of prostate cancer (PCa). It it considered to be a basis of medicamentous treatment of the first line of common hormone-sensitive prostate cancer. This therapy increases the overall and cancer-specific survivance of such patients, but has a number of side effects: it leads to metabolic disorders, endothelial dysfunction and, as a result, increases the risk of cardiovascular death. Such factors as the increase of life expectancy in the world, including Russia, the improvement of methods of diseases diagnosing, the growth of cancer incidence lead to an increase in the number of prostate cancer patients, which requires the improvement of treatment methods, evaluation of efficacy and safety of the therapy. Evaluation of the safety and effectiveness of hormone therapy, as well as the development of measures to reduce cardiovascular risks is one of the important tasks of modern medicine. The purpose of current review is to analyze the research work for these metabolic disorders, which demonstrates the possibility of these disorders’ correction in order to form an understanding of the role of the endocrinologist in management of the case.
Keywords: metabolic disorders, prostate cancer, androgen depriving therapy, adiposity, sarcopenia, carbohydrate metabolism disorders, metformin
Read entire article

Literature

  • Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 г. М., 2016.
  • Huggins C., Hodges C.V. Studies on Prostatic Cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293–7.
  • Urushima H., Inomata-Kurashiki Y., Nishimura K., Sumi R., Shimomura I., Nonomura N., Ito T., Maeda K. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Mail, 2015;18(2):72–6.
  • Keating N.L., O’Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006;24:4448–56.
  • Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., Litwin M.S. and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.
  • D’Amico A.V., Denham J.W., Crook J., Chen M.H., Goldhaber S.Z., Lamb D.S., Joseph D., Tai K.H., Malone S., Ludgate C., Steigler A., Kantoff P.W. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 2007;25:2420–5.
  • Tsai H.K., D’Amico A.V., Sadetsky N., Chen M.H., Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl. Cancer Inst. 2007;99:1516–24.
  • D’Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer.2008;113:3290–7.
  • Tayek J.A., Heber D., Byerley L.O., Steiner B., Rajfer J., Swerdloff R.S. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39:1314–9.
  • Smith J.C., Bennett S., Evans L.M., Kynaston H.G., Parmar M., Mason M.D., Cockcroft J.R., Scanlon M.F., Davies J.S. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 2001;86:4261–7.
  • Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., Kantoff P.W. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 2002;87:599–603.
  • Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., Reimondo G., Mari M., Ardissone P., De Luca S., Fasolis G., Fontana D., Rossetti S.R., Angeli A.; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 2002;167:2361–7.
  • Smith M.R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742–5.
  • Smith M.R., Lee H., McGovern F., Fallon M.A., Goode M., Zietman A.L., Finkelstein J.S. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188–94.
  • Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 2006;91:1305–8.
  • Dockery F., Bulpitt C.J., Agarwal S., Donaldson M., Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin. Sci. (Lond).2003;104:195–201.
  • Després J.P., Lamarche B., Mauriège P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 1996;334:952–7.
  • Pyörälä M., Miettinen H., Laakso M., Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation.1998;98:398–404.
  • А.С. Aметов. Сахарный диабет 2 типа: проблемы и решения. М., 2012.
  • Smith M.R., Lee H., Fallon M.A., Nathan D.M. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318–22.
  • Efstathiou J., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., Smith M.R. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 2009;27:92–9.
  • Roach M., Bae K., Speight J., Wolkov H.B., Rubin P., Lee R.J., Lawton C., Valicenti R., Grignon D., Pilepich M.V. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol.2008;26:585–91.
  • O’Farrell S., Garmo H., Holmberg L., Adolfsson J., Stattin P., Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol. 2015;33:1243–51.
  • Segal R.J., Reid R.D., Courneya K.S. et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol.2003;21:1653–9.
  • Cormie P., Galv~ao D.A., Spry N. et al. Can supervised exercise prevent treat-ment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.BJU Int.2015;115:256–66.
  • Gardner J.R., Livingston P.M., Fraser S.F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J. Clin. Oncol. 2014;32:335–46.
  • DPPOS. Lancet Diabetes Endocrinol, published online September 14, 2015. http://dx.doi.org/10.1016/S2213-8587(15)00291-0.


    • About the Autors

    Tatiana Ju. Demidova, MD, professor, head of the Department of endocrinology of the general medicine faculty of Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU». Тel.: +74991798506; e-mail: t.y.demidova@gmail.com.
    Elena Ju. Gritzkevich, assistant professor of the Department of endocrinology of the general medicine faculty of Federal State Budgetary Educational Institution of Higher Professional Education «N.I. Pirogov RNRMU». Тel.: +74991798506.
    Sergey V. Mishugin, PhD, high level certificate physician, state budgetary institution of Moscow healthcare Department «D.D. Pletnyov state clinical hospital»). Tel.: +74991646620.

    Back to Content

    Бионика Медиа